|
ASCO Journal Club by theMednet
ASCO is proud to announce a partnership with theMednet!
The Journal Club will feature papers from JCO
and will host authors and experts to answer questions from our community.
Featured Paper
Oncology Grand Rounds: Achieving a Cure Without Total Mesorectal Excision in Rectal Adenocarcinoma.
Original Report: Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results.
Rectal cancer, while a curable disease, has the downside of lifelong morbidities depending on curative-intent treatment options. The phase II NEO trial aims to investigate organ-sparing therapy and demonstrates the benefits of induction chemotherapy with mFOLFOX6/CAPOX allowing well-tolerated organ-preserving surgical therapy. This JCO Journal Club is intended to provide guidance on the efficacy and potential benefits of organ preservation strategies for management of patients with early-stage rectal cancer.
Expert Discussants:
Dr. William A. Hall is an Associate Professor of Radiation Oncology and Surgery at the Medical College of Wisconsin. He earned his medical degree at Loyola University Chicago, Stritch School of Medicine in 2009 and completed his residency in Radiation Oncology at Emory University in 2014. Dr. Hall's clinical and research interests include pancreatic cancer, prostate cancer, MRI guided radiation therapy, renal cell carcinoma and rectal cancer.
|
Dr. Hagen Kennecke is a Medical Oncologist and Medical Director of Gastrointestinal (GI) Oncology at Providence Cancer Institute in Portland, Oregon. He works passionately to improve the treatment, education and outcomes of those affected by colorectal and neuroendocrine cancers. Dr. Kennecke is an active clinician researcher and has received many research awards. In addition, he is the current chair of the United States National Cancer Institute (NCI) Rectal-Anal Cancer Task Force and the SWOG Recto-Anal Cancer Subcommittee. Previously, he served as chair of the Canadian Cancer Trials Group (CCTG) Rectal Cancer Disease Group. He earned his medical degree at Dalhousie University in 1997 then completed his residency and fellowship at University of British Columbia.
|
Other Papers from the Journal Club
- Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
- Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
- Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.
Popular Questions on theMednet
- What is the preferred second line, systemic therapy for NSCLC patients following first line chemoimmunotherapy?
- Would you use T-DXd or capecitabine/trastuzumab/tucatinib for HER2+ metastatic breast cancer with predominantly CNS progression after THP?
- How do you sequence capecitabine and olaparib, if at all, in patients with BRCA+ TNBC and residual disease after neoadjuvant chemotherapy?
- Based on TAILORx, what will be your approach to a pre-menopausal woman with a recurrence score 16-25?
- In patients with metastatic hormone receptor-positive, HER2-low breast cancer, how many and which lines of therapy would you recommend prior to using trastuzumab deruxtecan?